Minerva Surgical Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Todd Usen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	1.3yrs

Recent management updates

Recent updates

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Aug 11

Minerva downgraded at JPMorgan citing lowered guidance

Aug 10

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 10

Minerva Surgical - Uterine Play For Sale

Nov 02

CEO

Todd Usen (56 yo)

1.3yrs

Tenure

Mr. Todd Usen serves as President, Chief Executive Officer and Director at Minerva Surgical, Inc. since January 02, 2023. He was President of Olympus Corporation of the Americas. He served as President, Ch...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Todd Usen	President	1.3yrs	no data	no data
Greg Simbro	Vice President of Finance	less than a year	no data	no data
Erik Reese	Vice President of Sales	less than a year	no data	no data
Wendy Bowman	Vice President of Human Resources	no data	no data	0.016% $ 1.4
Evgueni Skalnyi	Chief Medical Officer	1.3yrs	US$388.99k	no data
Joanne Long	Vice President of Corporate Controller	3.3yrs	no data	0.026% $ 2.3

1.3yrs

Average Tenure

Experienced Management: UTRS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Todd Usen	President	1.3yrs	no data	no data
Uri Geiger	Director	1.3yrs	no data	no data
Catherine Coste	Independent Director	3.3yrs	US$187.50k	0.067% $ 5.9
Daniel Cohen	Independent Director	1.3yrs	no data	0% $ 0

1.3yrs

Average Tenure

55.5yo

Average Age

Experienced Board: UTRS's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Minerva Surgical Management

Management criteria checks 0/4

Key information

Recent management updates

Minerva Surgical, Inc. Announces the Resignation of Jill D. Anderson from the Board of Directors

Minerva Surgical, Inc. Announces Resignation of Ross A. Jaffe from the Board and from the Compensation Committee of the Board

High number of new directors

Minerva Surgical, Inc. Announces Resignation of David M. Renzi from Board of Directors and as Chairman of its Nominating and Corporate Governance Committee

Minerva Surgical, Inc. Announces Management Changes

Minerva Surgical, Inc. Appoints Derrick Sung as Director

Recent updates

Minerva Surgical Files Form 15

Minerva Surgical, Inc.(OTCPK:UTRS) dropped from NASDAQ Composite Index

Minerva Surgical, Inc. Announces Voluntary SEC Deregistration and Nasdaq Delisting

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Minerva Surgical, Inc. Announces the Resignation of Jill D. Anderson from the Board of Directors

Minerva Surgical, Inc. announced that it expects to receive $20 million in funding from Accelmed Partners

Consensus EPS estimates upgraded to US$0.22 loss

Minerva Surgical, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Minerva Surgical, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Minerva Surgical, Inc. Announces Resignation of Ross A. Jaffe from the Board and from the Compensation Committee of the Board

Minerva Surgical Provides Revenue Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings released: US$1.18 loss per share (vs US$3.06 loss in FY 2021)

Minerva Surgical, Inc. announced that it has received $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

High number of new directors

Minerva Surgical, Inc. Announces Resignation of David M. Renzi from Board of Directors and as Chairman of its Nominating and Corporate Governance Committee

Minerva Surgical Receives Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

Minerva Surgical, Inc. Announces Management Changes

Minerva Surgical, Inc. announced that it expects to receive $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

Consensus forecasts updated

Minerva Surgical, Inc. Provides Revenue Guidance for 2022

Third quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$5.00

Minerva Surgical Receives Notification Regarding Minimum Bid Price from the Listing Qualifications Department of the Nasdaq

Minerva Surgical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

U.S. Court of Appeals for the Federal Circuit Affirms Ruling on Minerva Surgical, Inc. and Hologic, Inc. Case

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Minerva downgraded at JPMorgan citing lowered guidance

Minerva Surgical, Inc. Revises Revenue Guidance for the Year 2022

Minerva Surgical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Minerva Surgical, Inc. Appoints Derrick Sung as Director

Minerva Surgical, Inc.(NasdaqGM:UTRS) dropped from Russell Microcap Value Index

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Earnings Guidance for 2022

Minerva Surgical, Inc., Annual General Meeting, Jun 09, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2022

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Full year 2021 earnings: EPS exceeds analyst expectations

Minerva Surgical, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

President recently bought US$123k worth of stock

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2021

Minerva Surgical - Uterine Play For Sale

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age